 Pyridones
"Pyridones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pyridine derivatives with one or more keto groups on the ring.
| Descriptor ID |
D011728
|
| MeSH Number(s) |
D03.383.725.791
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridones".
Below are MeSH descriptors whose meaning is more specific than "Pyridones".
This graph shows the total number of publications written about "Pyridones" by people in this website by year, and whether "Pyridones" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2006 | 2 | 0 | 2 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 3 | 0 | 3 | | 2013 | 3 | 4 | 7 | | 2014 | 2 | 2 | 4 | | 2015 | 7 | 2 | 9 | | 2016 | 5 | 7 | 12 | | 2017 | 5 | 2 | 7 | | 2018 | 3 | 4 | 7 | | 2019 | 2 | 1 | 3 | | 2020 | 5 | 6 | 11 | | 2021 | 5 | 6 | 11 | | 2022 | 0 | 8 | 8 | | 2023 | 2 | 9 | 11 | | 2024 | 9 | 6 | 15 | | 2025 | 3 | 7 | 10 | | 2026 | 1 | 4 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyridones" by people in Profiles.
-
Colasanti JA, Aldredge A, Niles-Carnes LV, Ochieng E, Pareek P, Robinson V, Anderson E, Castaneda M, Spralling H, Smith BL, Sumitani J, Paul Leue E, Moran CA, Lora M, Armstrong WS, Collins LF. Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South. Clin Infect Dis. 2026 Apr 30; 82(4):564-574.
-
Beck IA, Boyce CL, Bishop MD, Oldroyd AR, du Toit L, Saimen A, Ramarope KM, Hitchcock S, du Plessis NM, Mbogo L, Chohan BH, Maheria P, Oyaro P, Knowles K, Zhang Z, Brummel SS, Drain PK, Smith RA, Gottlieb GS, Abuogi L, Patel RC, Farquhar C, Wiznia A, Ruel TD, Rossouw TM, Hawes SE, Frenkel LM. HIV Resistance to Dolutegravir Varies With Coadministered Agents. Clin Infect Dis. 2026 Apr 30; 82(4):592-596.
-
Ombajo LA, Nkuranga J, Penner J, Kamau EW, Ismael N, Munseri P, Ayakaka I, Labhardt N, Wamalwa D, Ramgi P, Chissumba RM, Wagude J, Bakari M, Omodi V, Otieno E, Abuogi L, Patel R, Opondo C, Grint D, King'wara L, Macharia A, Mulwa A, Amoth P. The dolutegravir failure cohort: A multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocol. PLoS One. 2026; 21(3):e0330792.
-
Hollis RL, Miller A, Lankes HA, Wong KK, Rodgers W, Millan D, Carty K, Coleman RL, Moore KN, Alvarez Secord A, O'Malley DM, Chan JK, Hagemann AR, Gaillard S, Guntupalli SR, Edelson MI, Rose PG, Dorigo O, Banerjee S, Ewing A, Churchman M, Sood AK, Herrington CS, Gourley C, Gershenson DM. Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma. Clin Cancer Res. 2026 Feb 17; 32(4):724-734.
-
Sun S, Nikanjam M, Mirochnick M, Powis KM, Eke AC, Stek A, Arora P, Cressey TR, Brooks KM, Best BM, Capparelli EV, Momper JD. Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure. J Clin Pharmacol. 2026 Jan; 66(1):e70134.
-
Tomita Y, Link G, Ge Y, Gold ERH, Racanelli A, Cardona HJ, Romero M, Gadd S, Watanabe J, Uchida E, Hashizume R, Takata N, Pinero G, Hambardzumyan D, Spasojevic I, Hu G, Hennika T, Brat DJ, Green AL, Becher OJ. Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models. PLoS One. 2025; 20(12):e0323235.
-
Gartland M, Wang X, Liao Q, Li B, Du F, Krystal M, Tenorio AR, Pierce A, Castillo-Mancilla JR. Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study. HIV Med. 2026 Mar; 27(3):386-396.
-
Weitz JI, Kithcart AP, O'Brien MP, Levy O, Marin E, Onisko M, Mohammadi KA, Li D, Meagher KA, Chang HH, Olenchock BA, Gutstein DE, Segers A, Roberts RS, Bonaca MP, Raskob GE. Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials. Lancet. 2025 Nov 29; 406(10519):2551-2563.
-
Pasco R, Hayden FG, Meyers LA. Modeling Influenza Antiviral Strategies: Reducing Burden and Preventing Resistance. J Infect Dis. 2025 Oct 17; 232(Supplement_3):S299-S308.
-
Scallon AJ, Maheria P, Oyaro P, Thomas KK, Chohan BH, Odhiambo F, Brown E, Ochomo E, Karauki E, Yongo N, Hassan SA, Bishop MD, Beck IA, Boyce C, Frenkel LM, Abuogi L, Patel RC. Clinical, Psychosocial, and Structural Factors Associated with the Detection of HIV Drug Resistance in Children Living with HIV in Kisumu, Kenya: Secondary Analysis of Data from the Opt4Kids Study. Viruses. 2025 Sep 16; 17(9).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|